Ligand Pharmaceuticals Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ligand Pharmaceuticals stock.
View analyst ratings for Ligand Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Ligand Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ligand Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Ligand Pharmaceuticals.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its quarterly earnings results on Sunday, May, 2nd. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.13 by $0.28. The biotechnology company earned $55.10 million during the quarter, compared to the consensus estimate of $63 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 8.50% and a net margin of 18.83%. The firm's revenue for the quarter was up 66.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 EPS.
View Ligand Pharmaceuticals' earnings history.

Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LGND stock has increased by 29.5% and is now trading at $118.96.
View which stocks have been most impacted by COVID-19.

Ligand Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, July, 29th. The company provided earnings per share guidance of $5.800-$6.050 for the period, compared to the Thomson Reuters consensus estimate of $6.120. The company issued revenue guidance of $265 million-$275 million, compared to the consensus revenue estimate of $280.44 million.

6 Wall Street analysts have issued 1 year target prices for Ligand Pharmaceuticals' shares. Their forecasts range from $190.00 to $310.00. On average, they anticipate Ligand Pharmaceuticals' share price to reach $228.75 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for Ligand Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated Ligand Pharmaceuticals CEO John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among Ligand Pharmaceuticals' employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of LGND's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Oregon Public Employees Retirement Fund (0.03%) and New Mexico Educational Retirement Board (0.02%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, Matthew W Foehr, Sunil Patel and Todd C Davis.
View institutional ownership trends for Ligand Pharmaceuticals.

LGND stock was bought by a variety of institutional investors in the last quarter, including New Mexico Educational Retirement Board, and Oregon Public Employees Retirement Fund. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins, Matthew W Foehr, and Sunil Patel.
View insider buying and selling activity for Ligand Pharmaceuticals or or view top insider-buying stocks.

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LGND stock can currently be purchased for approximately $118.96.

Ligand Pharmaceuticals has a market capitalization of $1.98 billion and generates $186.42 million in revenue each year. The biotechnology company earns $-2,980,000.00 in net income (profit) each year or $3.13 on an earnings per share basis.

Ligand Pharmaceuticals employs 155 workers across the globe.

The official website for Ligand Pharmaceuticals is www.ligand.com.

Ligand Pharmaceuticals is headquartered at 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]